Dose fractionation in 131I-metaiodobenzylguanidine (MIBG) therapy: should the tumour biology and intent of therapy be the guide?

被引：0
作者：
Sandip Basu
机构：
[1] Tata Memorial Hospital Annexe,Radiation Medicine Centre (B.A.R.C)
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2010年 / 37卷
关键词：
Paraganglioma; Phaeochromocytoma; Malignant Phaeochromocytoma; Metastatic Neuroendocrine Tumour; Neural Crest Tumour;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1798 / 1799
页数：1
相关论文
共 22 条
  • [1] Dose fractionation in 131I-metaiodobenzylguanidine (MIBG) therapy: should the tumour biology and intent of therapy be the guide?
    Basu, Sandip
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (09) : 1798 - 1799
  • [2] Malignant pheochromocytomas and paragangliomas -: A phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)
    Fitzgerald, Paul A.
    Goldsby, Robert E.
    Huberty, John P.
    Price, David C.
    Hawkins, Randall A.
    Veatch, Janet J.
    Dela Cruz, Filemon
    Jahan, Thierry M.
    Linker, Charles A.
    Damon, Lloyd
    Matthay, Katherine K.
    PHEOCHROMOCYTOMA, 2006, 1073 : 465 - 490
  • [3] High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma
    Rose, B
    Matthay, KK
    Price, D
    Huberty, J
    Klencke, B
    Norton, JA
    Fitzgerald, PA
    CANCER, 2003, 98 (02) : 239 - 248
  • [4] 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma
    Jungels, Christiane
    Karfis, Ioannis
    CURRENT OPINION IN ONCOLOGY, 2021, 33 (01) : 33 - 39
  • [5] Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results, from a multicenter observational registry
    Yoshinaga, Keiichiro
    Oriuchi, Noboru
    Wakabayashi, Hiroshi
    Tomiyama, Yuuki
    Jinguji, Megumi
    Higuchi, Tetsuya
    Kayano, Daiki
    Fukuoka, Makoto
    Inaki, Anri
    Toratani, Ayane
    Okamoto, Shozo
    Shiga, Tohru
    Ito, Yoichi M.
    Nakajo, Masatoyo
    Nakajo, Masayuki
    Kinuya, Seigo
    ENDOCRINE JOURNAL, 2014, 61 (12) : 1171 - 1180
  • [6] 131I-MIBG Therapy in metastatic phaeochromocytoma and paraganglioma
    Gedik, Gonca Kara
    Hoefnagel, Cornelis A.
    Bais, Evert
    Olmos, Renato A. Valdes
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (04) : 725 - 733
  • [7] 131I-MIBG Therapy in metastatic phaeochromocytoma and paraganglioma
    Gonca Kara Gedik
    Cornelis A. Hoefnagel
    Evert Bais
    Renato A. Valdés Olmos
    European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35 : 725 - 733
  • [8] Current Consensus on I-131 MIBG Therapy
    Kayano D.
    Kinuya S.
    Nuclear Medicine and Molecular Imaging, 2018, 52 (4) : 254 - 265
  • [9] Low-dose 123I-metaiodobenzylguanidine diagnostic scan is inferior to 131I-metaiodobenzylguanidine posttreatment scan in detection of malignant pheochromocytoma and paraganglioma
    Kayano, Daiki
    Taki, Junichi
    Fukuoka, Makoto
    Wakabayashi, Hiroshi
    Inaki, Anri
    Nakamura, Ayane
    Kinuya, Seigo
    NUCLEAR MEDICINE COMMUNICATIONS, 2011, 32 (10) : 941 - 946
  • [10] Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma
    Nakazawa, Azusa
    Higuchi, Tetsuya
    Oriuchi, Noboru
    Arisaka, Yukiko
    Endo, Keigo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (10) : 1869 - 1875
123